Disclaimer: This information is provided for the use of physicians and other licensed health care practitioners only. This information is not for use by consumers. The information and or products are not intended for use by consumers or physicians as a means to cure, treat, prevent, diagnose or mitigate any disease or other medical condition. The information contained in this document is in no way to be taken as prescriptive nor to replace the physicians duty of care and personalised care practices.
By Michael Jurgelewicz, DC, DACBN, DCBCN
Designs For Health
Omega-3 Intake May Help Decrease Colon Cancer Mortality After Diagnosis
According to a new study published in Gut, researchers concluded that a high dietary intake of omega-3 fatty acids may help decrease mortality in patients with colon cancer.
Previous research has demonstrated that omega-3 fatty acids suppress tumor growth and decrease angiogenesis to malignant cells. For example, two months ago I shared a new study published in the journal Molecular Cancer Therapeutics, where researchers demonstrated that docosahexaenoic acid (DHA) helps reduce renal cell carcinoma invasiveness, growth rate, and blood vessel growth when combined with the anti-cancer therapy regorafenib. In addition, in a study published in the Journal of Pharmacology and Experimental Therapeutics, researchers at Washington State University found a mechanism by which omega-3 fatty acids inhibit the growth and spread of prostate cancer cells.
In this new study, the results were based on two large, long term studies, these being the Nurses' Health Study of 121,700 US registered female nurses and the Health Professionals Follow Up Study of 51, 529 male health professionals. All participants completed a detailed health history which was repeated every two years subsequently.
The information included any diagnosis of bowel cancer as well as and other risk factors. In addition, a diet diary was collected and updated every four years using Food Frequency Questionnaires.
In this study, there were 1,659 participants who developed bowel cancer and as a result, 561 died. One hundred and sixty nine of these deaths were a result of the disease during an average monitoring period of 10.5 years.
Participants who had been diagnosed with colon cancer and whose diets contained higher levels of omega-3 fatty acids had a decreased mortality rate from the disease. Thus, there was an inverse relationship between omega-3 fatty acid intake and risk of death. The higher dose or intake of fish oil was associated with a lower risk of bowel cancer. This was also true after adjusting the intake prior to the diagnosis. Patients who consumed less omega-3 fatty acids daily had a 41% lower risk of dying from cancer once they increased their intake at the time of diagnosis. This reduced risk was associated with a combination of dietary sources and supplements.
The researchers determined that increasing the omega-3 intake of 0.15 g daily after diagnosis was associated with a 70% reduction in mortality. On the other hand, reducing daily essential fatty acid intake was associated with a 10% increased risk in mortality.
Designs For Health OmegAvail Ultra
OmegAvail Ultra carries a TruTG seal, your assurance that the fish oils are in their natural triglyceride form and are of unmatched TG potency. Fish oils in the TG (triglyceride) form are as they occur in nature. Fish oil blends and concentrates bearing the TruTG seal are 90% to 100% triglyceride (TG) bound omega-3 oils ,40%-50% higher than the industry standard for TG fish oil concentrate products!
This product includes lipase for maximal bioavailability.
Full Fatty Acid + Trans Fat Profile
The Full Fatty Acid Profile (including Omega-3-Index and Trans Fats) measures:
- Trans Fat Index
- Omega-6/Omega-3 Ratio
- AA/EPA Ratio
- Full Fatty Acid Profile
For just £89.00.
Source: Mingyang Song, Xuehong Zhang, Jeffrey A Meyerhardt, Edward L Giovannucci, Shuji Ogino, Charles S Fuchs, Andrew T Chan. Marine ω-3 polyunsaturated fatty acid intake and survival after colorectal cancer diagnosis. Gut, 2016; gutjnl-2016-311990 DOI: 10.1136/gutjnl-2016-311990